|
|
|
05.06.25 - 13:03
|
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 23,400 shares of the company's common stock to one new employee (the “Inducement Grants”) on June 2, 2025 (the “Grant Date”). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing pric...
|
|
|
|
|
|
|
|
|
|
|
02.05.25 - 13:06
|
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company's Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 204,150 shares of the company's common stock to 13 new employees (the “Inducement Grants”) on May 1, 2025 (the “Grant Date”). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing pric...
|
|
|
07.04.25 - 13:06
|
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors (Business Wire)
|
|
|
- Mr. Ajer was most recently Chief Commercial Officer at BioMarin -
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors.
Mr. Ajer has more than 25 years of experience driving commercialization for rare diseases and specialty medicines, including leading commercial planning for late-stage pipeline programs, product marketing, reimbursement, and sales operations. He most recently served as the Executive Vice President and Chief Commercial Officer (CCO) at BioMarin Pharmaceutical, where he joined in 2005 as one of the first sales and marketing employees and subsequently held roles of increasing responsibility that helped to establish BioMarin's commercial infrastructure and global footprint. Mr. Ajer had direct responsibility for the launch of 5 brands during his time as CCO. Prior to...
|
|
|
10.03.25 - 12:03
|
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 113,200 shares of the company's common stock to nine new employees (the “New-Hire Inducement Grants”) on March 3, 2025.
The New-Hire Inducement Grants have an exercise price per share that is equal to the closing price of Viridian's common stock on March 3, 2025. The New-Hire Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 36 equal monthly installments, subject to each employee's continued employment with Viridian through t...
|
|
|
|
|
|
|
27.02.25 - 13:03
|
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
|
|
|
- Reported positive topline phase 3 data for veligrotug from both THRIVE and THRIVE-2 in patients with active and chronic thyroid eye disease (TED); veligrotug has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 -
- REVEAL-1 and REVEAL-2, phase 3 clinical trials assessing Q4W or Q8W subcutaneous (SC) VRDN-003 in active and chronic TED, progressing as planned and on track for topline data for both trials in the first half of 2026 -
- Proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter of 2025 for VRDN-006, an Fc fragment inhibitor of the neonatal Fc receptor (FcRn) -
- VRDN-008, a bispecific FcRn inhibitor with an extended half-life, expected to have additional preclinical data in 2025 with an Investigational New Drug (IND) submission planned for year-end 2025 -
- Viridian appoints Radhika Tripuraneni, M....
|
|
|
|
|
|
|
06.02.25 - 22:03
|
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the Compensation Committee of the company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 527,750 shares of the company's common stock to 15 new employees (the “Inducement Grants”) on February 3, 2025 (the “Grant Date”). The Inducement Grants have been granted outside of the company's Amended and Restated 2016 Equity Incentive Plan (the “Plan”) but remain subject to the terms and conditions of such Plan. The Inducement Grants were granted as an inducement material to these individuals entering into employment with Viridian in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grants have an exercise price per share that is equal to the closing price of V...
|
|
|
06.02.25 - 12:00
|
Viridian Metals Ins. wechselt von TSXV zu CSE (Rohstoff-Welt)
|
|
|
Viridian gibt bekannt, dass das Unternehmen von der CSE die Genehmigung zur Notierung seiner Stammaktien an der CSE erhalten hat. Darüber hinaus hat das Unternehmen bei der TSXV einen Antrag auf freiwilliges Delisting seiner Aktien von der TSXV eingereicht. Das Unternehmen hat sich für ein Delisting von der TSXV und eine Notierung an der CSE entschieden, da die Gebührenstruktur der CSE niedriger ist und es dem Unternehmen dadurch ermöglicht wird, ein Maximum an Ressourcen auf die Exploration seiner Rohstoffliegenschaften zu konzentrieren....
|
|
|
|
|
|
|
|
|
08.01.25 - 13:06
|
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease (Business Wire)
|
|
|
- Veligrotug, with recent positive phase 3 topline data in both active and chronic thyroid eye disease (TED), has the potential to transform the standard of care in TED with a differentiated clinical profile achieved with less drug and fewer infusions; Biologics License Application (BLA) submission on track for second half of 2025 -
- REVEAL-1 and REVEAL-2, phase 3 clinical trials for subcutaneous (SC) VRDN-003 in active and chronic TED respectively, are currently dosing patients; topline data for both trials, which are evaluating VRDN-003 dosed Q4W or Q8W, is on track for the first half of 2026 -
- Investigational New Drug (IND) submitted in December 2024 for VRDN-006, an Fc fragment inhibitor of the neonatal Fc receptor (FcRn); proof-of-concept IgG reduction clinical data in healthy volunteers anticipated in the third quarter of 2025 -
- VRDN-008, a bispecific FcRn inhibitor with an extended half-life, progressing with preclinical studies as planned; additional preclinical data expected in 2025 with an ...
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
